logo-loader
viewAvacta Group PLC

Avacta's Alastair Smith updates on selection of cancer candidate to take into clinic

Avacta Group PLC's (LON:AVCT) Alastair Smith tells Proactive London's Andrew Scott they've selected the cancer drug candidate they'll be taking into first-in-human clinical trials.

It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.

Quick facts: Avacta Group PLC

Price: 22.3 GBX

AIM:AVCT
Market: AIM
Market Cap: £39.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Coinsilium's Eddy Travia details MoU and strategic...

Coinsilium Group Limited (LON:COIN) CEO Eddy Travia caught up with Proactive London's Andrew Scott after announcing a strategic investment agreement with IOV Labs. Alongside the investment deal, Travia says they've also agreed an MOU with IOV to establish a joint venture in Singapore. IOV...

8 hours, 2 minutes ago

2 min read